Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-5175

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-5175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5175 9)

Label for Losartan Potassium 50 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label shows a bottle containing 90 tablets with NDC 68071-5175-9. It includes barcodes, manufacturer information (Matero Labs Limited India and NuCare Pharmaceuticals, Orange, CA), and storage instructions to keep at controlled temperatures of 68-77°F. The label features warnings and notes it is a prescription-only medication.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line chart comparing the percentage of patients with a primary endpoint over a 60-month study period between two treatments: Atenolol (dotted line) and Losartan potassium (solid line). The graph shows adjusted risk reduction data and statistical significance values.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over study months between Losartan Potassium and Atenolol. The graph shows a lower incidence rate for Losartan Potassium, with an adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot illustrating primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. The chart displays event rates (%) for primary composite and stroke (fatal/non-fatal) outcomes across various age, gender, race, ISH, diabetes, and cardiovascular disease history categories, with hazard ratios and 95% confidence intervals represented by squares and diamonds.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan potassium versus placebo. The vertical axis represents the percentage of patients, and the horizontal axis shows time in months. The graph indicates a risk reduction associated with Losartan potassium.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium showing its molecular arrangement including a chlorine-substituted biphenyl, a tetrazole ring, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.